https://orcid.org/0000-0002-2004-3724
Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Jiaju Zhuo, Beibei Liang, Huan Zhang, Yulong Chi & Yun Cai. (2023) An overview of gram-negative bacteria with difficult-to-treat resistance: definition, prevalence, and treatment options. Expert Review of Anti-infective Therapy 21:11, pages 1203-1212.
Read now
Read now
Daniele Roberto Giacobbe, Ilias Karaiskos & Matteo Bassetti. (2022) How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients?. Expert Opinion on Pharmacotherapy 23:1, pages 5-8.
Read now
Read now
Articles from other publishers (17)
Dongxia Wang, Jakub Baudys, Sarah H. Osman & John R. Barr. (2023) Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2. Analytical and Bioanalytical Chemistry 415:19, pages 4779-4793.
Crossref
Crossref
Maria Mazzitelli, Dario Gregori, Lolita Sasset, Marco Trevenzoli, Vincenzo Scaglione, Sara Lo Menzo, Serena Marinello, Daniele Mengato, Francesca Venturini, Ivo Tiberio, Paolo Navalesi & Annamaria Cattelan. (2023) Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic. Microorganisms 11:4, pages 984.
Crossref
Crossref
Aniket Naha & Sudha Ramaiah. (2023) Novel Antimicrobial Peptide SAAP Mutant as a Better Adjuvant to Sulbactam-Based Treatments Against Clinical Strains of XDR Acinetobacter baumannii. Probiotics and Antimicrobial Proteins.
Crossref
Crossref
Maria Luisa Introvigne, Trevor J. Beardsley, Micah C. Fernando, David A. Leonard, Bradley J. Wallar, Susan D. Rudin, Magdalena A. Taracila, Philip N. Rather, Jennifer M. Colquhoun, Shaina Song, Francesco Fini, Kristine M. Hujer, Andrea M. Hujer, Fabio Prati, Rachel A. Powers, Robert A. Bonomo & Emilia Caselli. (2023) Sulfonamidoboronic Acids as “Cross-Class” Inhibitors of an Expanded-Spectrum Class C Cephalosporinase, ADC-33, and a Class D Carbapenemase, OXA-24/40: Strategic Compound Design to Combat Resistance in Acinetobacter baumannii. Antibiotics 12:4, pages 644.
Crossref
Crossref
Matteo Bassetti, Antonio Vena, Nadia Castaldo, Daniele Roberto Giacobbe, Maddalena Peghin & Paolo Antonio Grossi. (2022) Clinical evidence supporting cefiderocol for serious Acinetobacter baumannii infections. Current Opinion in Infectious Diseases 35:6, pages 545-551.
Crossref
Crossref
Matteo Bassetti, Souha S Kanj, Pattarachai Kiratisin, Camilla Rodrigues, David Van Duin, María Virginia Villegas & Yunsong Yu. (2022) Early appropriate diagnostics and treatment of MDR Gram-negative infections. JAC-Antimicrobial Resistance 4:5.
Crossref
Crossref
Guido Granata, Fabrizio Taglietti, Francesco Schiavone & Nicola Petrosillo. (2022) Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Systematic Review. Journal of Clinical Medicine 11:12, pages 3258.
Crossref
Crossref
Farshid Danesh & Somayeh GhaviDel. (2022) A Scientometric Study of the Intellectual Structure of Researchers' Publications: Acinetobacter baumannii. Iranian Journal of Medical Microbiology 16:3, pages 197-211.
Crossref
Crossref
Massimiliano Marazzato, Daniela Scribano, Meysam Sarshar, Francesca Brunetti, Silvia Fillo, Antonella Fortunato, Florigio Lista, Anna Teresa Palamara, Carlo Zagaglia & Cecilia Ambrosi. (2022) Genetic Diversity of Antimicrobial Resistance and Key Virulence Features in Two Extensively Drug-Resistant Acinetobacter baumannii Isolates. International Journal of Environmental Research and Public Health 19:5, pages 2870.
Crossref
Crossref
Jinfeng Bao, Lu Xie, Yating Ma, Ran An, Bing Gu & Chengbin Wang. (2022) Proteomic and Transcriptomic Analyses Indicate Reduced Biofilm-Forming Abilities in Cefiderocol-Resistant Klebsiella pneumoniae. Frontiers in Microbiology 12.
Crossref
Crossref
Roshan Kumar, Utkarsh Sood, Jasvinder Kaur, Shailly Anand, Vipin Gupta, Kishor Sureshbhai Patil & Rup Lal. (2021) The rising dominance of microbiology: what to expect in the next 15 years?. Microbial Biotechnology 15:1, pages 110-128.
Crossref
Crossref
Matteo Bassetti, Chiara Russo, Antonio Vena & Daniele Roberto Giacobbe. (2021) New antibiotics for the treatment of nonfermenting Gram-negative bacteria. Current Opinion in Infectious Diseases 34:6, pages 701-709.
Crossref
Crossref
Aniket Naha, Saranya Vijayakumar, Binesh Lal, Baby A. Shankar, Suriya Chandran, Sudha Ramaiah, Balaji Veeraraghavan & Anand Anbarasu. (2021)
Genome sequencing and molecular characterisation of XDR
Acinetobacter baumannii
reveal complexities in resistance: Novel combination of sulbactam–durlobactam holds promise for therapeutic intervention
. Journal of Cellular Biochemistry 122:12, pages 1946-1957.
Crossref
Crossref
Lorenzo Volpicelli, Mario Venditti, Giancarlo Ceccarelli & Alessandra Oliva. (2021) Place in Therapy of the Newly Available Armamentarium for Multi-Drug-Resistant Gram-Negative Pathogens: Proposal of a Prescription Algorithm. Antibiotics 10:12, pages 1475.
Crossref
Crossref
Matteo Bassetti, Antonio Vena, Daniele Roberto Giacobbe & Nadia Castaldo. (2021) Management of Infections Caused by Multidrug-resistant Gram-negative Pathogens: Recent Advances and Future Directions. Archives of Medical Research 52:8, pages 817-827.
Crossref
Crossref
Sunil Kumar, Razique Anwer & Arezki Azzi. (2021) Virulence Potential and Treatment Options of Multidrug-Resistant (MDR) Acinetobacter baumannii. Microorganisms 9:10, pages 2104.
Crossref
Crossref
Abolfazl Jahangiri, Parviz Owlia, Iraj Rasooli, Jafar Salimian, Ehsan Derakhshanifar, Zahra Aghajani, Sajad Abdollahi, Saeed Khalili, Daryush Talei & Elham Darzi Eslam. (2021) Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection. Scientific Reports 11:1.
Crossref
Crossref